- CHASE clinical trial interim review demonstrated beneficial changes in markers of cardiovascular health
- Composition of matter patent for CDX-101 filed to extend patent coverage to 2040
- ZanthoSyn® sales rebound in the second half of 2019 with stronger correlation of sell-in/sell-through patterns
- $3,360,000 raised in 2019
PR Newswire
HONOLULU, March 30, 2020